CASE REPORTSHemophilia A and von Willebrand deficiency: therapeutic implicationsBasso, Mariaa; Lazzareschi, Ilariab,c; Curatola, Antoniettab; Di Gennaro, Leonardoa; Buonsenso, Danilob,c; Gatto, Antoniob; De Candia, Ericaa,d; De Cristofaro, Raimondoa,dAuthor Information aServizio di Malattie Emorragiche e Trombotiche, Area di Ematologia bDipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, UOC Pediatria, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS cIstituto di Pediatria, Università Cattolica del Sacro Cuore dIstituto di Medicina Interna e Geriatria, Università Cattolica Del Sacro Cuore, Roma, Italia Correspondence to Antonietta Curatola, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, UOC Pediatria, Fondazione Policlinico Universitario ‘A. Gemelli’ IRCCS, Roma, Italia. Tel: +39 0630154475; fax: +39 063383211; e-mail: email@example.com Received 16 December, 2019 Revised 13 February, 2020 Accepted 24 February, 2020 Blood Coagulation & Fibrinolysis: August 2020 - Volume 31 - Issue 6 - p 397-401 doi: 10.1097/MBC.0000000000000908 Buy Metrics Abstract Hemophilia A is an X-linked bleeding disorder caused by a deficiency of factor VIII. Depending on the factor VIII activity in patient's plasma, we can have three different forms of hemophilia A: mild (5–40 IU/dl), moderate (1–5 IU/dl) and severe (<1 IU/dl). The most common symptoms include recurrent bleeding episodes of soft tissues and joints. The treatment is based on the prophylactic use of clotting factor concentrates to prevent bleeding episodes. We describe three cases of patients with initially diagnosis of hemophilia A that show different clinical severity, undergoing prophylactic therapies with low benefit. In these patients, the dosage of von Willebrand antigen revealed either low level or absence of this factor, which in one case was caused by the occurrence of a type III form of von Willebrand disease. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.